272-50-4 Usage
Uses
Used in Organometallic Chemistry and Catalysis:
1,4,6-Triazaindene is used as a ligand for its ability to coordinate with metal ions, which is crucial in organometallic chemistry and catalysis. This coordination capability enhances the reactivity and selectivity of catalytic processes.
Used in the Production of OLEDs and Organic Electronic Devices:
1,4,6-Triazaindene is utilized as a component in the manufacturing of OLEDs and other organic electronic devices due to its electronic properties, contributing to the efficiency and performance of these devices.
Used in Pharmaceutical Synthesis:
1,4,6-Triazaindene is employed as an intermediate in the synthesis of various pharmaceuticals, leveraging its reactivity and structural features to produce desired medicinal compounds.
Used in Materials Science:
1,4,6-Triazaindene is used in the field of materials science for the development of new functional materials and polymers, where its unique properties can be harnessed to create innovative materials with specific applications.
Check Digit Verification of cas no
The CAS Registry Mumber 272-50-4 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 2,7 and 2 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 272-50:
(5*2)+(4*7)+(3*2)+(2*5)+(1*0)=54
54 % 10 = 4
So 272-50-4 is a valid CAS Registry Number.
InChI:InChI=1/C6H5N3/c1-2-8-6-3-7-4-9-5(1)6/h1-4,8H
272-50-4Relevant articles and documents
N-CONTAINING HETEROCYCLIC COMPOUNDS
-
Page/Page column 99, (2009/06/27)
The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.
